Compugen (CGEN) Projected to Post Quarterly Earnings on Monday

Compugen (NASDAQ:CGEN) will likely be releasing its Q1 2025 earnings data before the market opens on Monday, May 19th. Analysts expect Compugen to post earnings of ($0.06) per share and revenue of $3.70 million for the quarter.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.14). The company had revenue of $1.47 million during the quarter, compared to the consensus estimate of $17.47 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Price Performance

Shares of NASDAQ CGEN opened at $1.26 on Monday. Compugen has a 1-year low of $1.13 and a 1-year high of $2.66. The business has a fifty day moving average price of $1.46 and a 200 day moving average price of $1.70. The stock has a market capitalization of $112.44 million, a P/E ratio of 63.00 and a beta of 2.61.

Analyst Ratings Changes

Several analysts have commented on the stock. Oppenheimer began coverage on shares of Compugen in a research report on Monday, January 13th. They set an “outperform” rating and a $4.00 price target for the company. StockNews.com downgraded shares of Compugen from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.